Abdul Salam Khan

Abdul Salam Khan

Auto-generated profile, based on publicly available information

Abdul Salam Khan

Department of Oncology-Pathology, Immune and Gene Therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2012 in Leukemia
Verified
Journal Article
Closed access
ADA H Daneshmanesh
A H Daneshmanesh
Mohammad Hojjat-FarsangiMohammad Hojjat-Farsangi
Mohammad Hojjat-Farsangi
AKA S Khan
A S Khan
MJMahmood Jeddi-Tehrani
Mahmood Jeddi-Tehrani
MAMohammad Mehdi Akhondi
Mohammad Mehdi Akhondi
HMH Mellstedt
H Mellstedt

1 December 2014 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
Mohammad Hojjat-FarsangiMohammad Hojjat-Farsangi
Mohammad Hojjat-Farsangi
AMAli Moshfegh
Ali Moshfegh
ADAmir Hossein Daneshmanesh
Amir Hossein Daneshmanesh
AKAbdul Salam Khan
Abdul Salam Khan
EMEva Mikaelsson
Eva Mikaelsson
HMHåkan Mellstedt
Håkan Mellstedt

24 October 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Mohammad Hojjat-FarsangiMohammad Hojjat-Farsangi
Mohammad Hojjat-Farsangi
AKAbdul Salam Khan
Abdul Salam Khan
ADAmir Hossein Daneshmanesh
Amir Hossein Daneshmanesh
AMAli Moshfegh
Ali Moshfegh
ÅSÅsa Sandin
Åsa Sandin
HMHåkan Mellstedt
Håkan Mellstedt
Phosphorylation of receptor tyrosine kinases (RTKs) has a key role in cellular functions contributing to the malignant phenotype of tumor cells. We and others have previously demonstrated that RTK ROR1 is overexpressed in chronic lymphocytic leukemia (CLL). Silencing siRNA downregulated ROR1 and induced apoptosis of CLL cells. In the present study we analysed ROR1 isoforms and the phosphorylation pattern in CLL cells (n=38) applying western blot and flow-cytometry using anti-ROR1 antibodies and an anti-phospho-ROR1 antibody against the TK domain. Two major ROR1 bands with the size of 105 and 130 kDa respectively were identified, presumably representing unglycosylated (immature) and glycosylated (mature) ROR1 respectively as well as a 260 kDa band which may represent dimerized ROR1. A ROR1 band of 64 kDa that may correspond to a C-terminal fragment was also noted, present only in the nucleus. The 105 kDa ROR1 isoform was more frequently expressed in non-progressive as compared to progressive CLL patients (p=0.03). The 64, 105, 130 and 260 kDa bands were constitutively phosphorylated both at tyrosine and serine residues. Phosphorylation intensity of the mature (130 kDa) isoform was significantly higher in progressive than in non-progressive disease (p<0.001). Incubation of CLL cells with a mouse anti-ROR1 KNG or an anti-ROR1 CRD mAb respectively induced dephosphorylation of ROR1 before entering apoptosis. In conclusion CLL cells expressed different isoforms of ROR1 which were constitutively phosphorylated. The mature, phosphorylated ROR1 isoform was associated with a progressive disease stage. Targeting ROR1 by mAbs induced specific dephosphorylation and leukemic cell death. ROR1 might be an interesting therapeutic target.

19 November 2014 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
ADAmir Hossein Daneshmanesh
Amir Hossein Daneshmanesh
Mohammad Hojjat-FarsangiMohammad Hojjat-Farsangi
Mohammad Hojjat-Farsangi
AMAli Moshfegh
Ali Moshfegh
AKAbdul Salam Khan
Abdul Salam Khan
EMEva Mikaelsson
Eva Mikaelsson
HMHåkan Mellstedt
Håkan Mellstedt